Last week, the biotech company Cyxone announced that the first patient has been screened in the phase II trial with their candidate drug Rabeximod in patients suffering from moderate Covid-19. The aim of the treatment is to prevent a more serious progression of the condition and ultimately to save lives. BioStock reached out to COO Malin Berthold for a comment.

Read the full interview with Malin Berthold at biostock.se:

https://www.biostock.se/en/cyxones-covid-19-trial-with-rabeximod-initiated-in-europe/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/cyxone/r/biostock--cyxone-s-covid-19-trial-with-rabeximod-initiated-in-europe,c3272391

(c) 2021 Cision. All rights reserved., source Press Releases - English